International Pharmaceutical Development Consortium to partner with PharmaJet for delivery of COVID-19 DNA Vaccine, GX-19GOLDEN, Colo. — September 15, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Stratis® Needle-free Injection System will be used to deliver a novel DNA vaccine against COVID-19 (GX-19) which is being developed by an international consortium led by Genexine, a leading biotherapeutics company headquartered in South Korea. The consortium also includes the International Vaccine Institute (IVI), Binex, GenNBio, Korea Advanced Institute for Science and Technology, and Pohang University of Science and Technology. Details
PharmaJet and Abnova partner to develop and deliver COVID-19 mRNA Vaccine using Needle-free Injection technology
GOLDEN, Colo. — May 19, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world’s largest antibody manufacturer, based in Taiwan.
Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs for responding to SARS-CoV-2, including a novel adjuvant that can further increase the effectiveness of their mRNA candidate.Details
GOLDEN, Colo. — April 28, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced the appointment of Chris Cappello to President and Chief Executive Officer. Chris replaces Ron Lowy, who was appointed Executive Chairman of the board.
Ron Lowy, Executive Chairman, PharmaJet Inc. said, “ In the 10 years that Chris has worked for PharmaJet he has shown the ability to lead the organization and expand on our important collaborations with groups such as the US federal government, the World Health Organization, multiple pharmaceutical partnerships…Details
Immunomic Therapeutics Forms Collaboration with EpiVax and PharmaJet to Develop Novel Vaccine Candidate Against COVID-19 Using its Investigational UNITE PlatformROCKVILLE, MD, PROVIDENCE, RI, and GOLDEN, CO — April 09, 2020 — Immunomic Therapeutics, Inc., a privately held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms, announced today that it is developing a nucleic acid vaccine candidate against COVID-19 leveraging its investigational UNITE platform for prevention of the novel coronavirus disease caused by SARS-Cov-2 coronavirus. Details
PharmaJet Announces Appointment of Pharmaceutical Executive Dr. Marie Mazur to the Board of DirectorsGOLDEN, Colo. — March 25, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Dr. Marie Mazur, has been appointed to its Board of Directors. Dr. Mazur is a global business executive with over 30 years of experience growing revenue and profits for major vaccine and pharmaceutical companies.
Ron Lowy, Executive Chairman, PharmaJet Inc. said, “we are very pleased to welcome Dr. Mazur to the PharmaJet Board of Directors." Details